Terence Flynn
Stock Analyst at Morgan Stanley
(3.91)
# 651
Out of 4,996 analysts
201
Total ratings
60.19%
Success rate
7.26%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Overweight | $23 → $22 | $4.05 | +443.21% | 2 | Aug 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $63 → $54 | $15.00 | +260.00% | 3 | Aug 12, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $32 → $33 | $23.76 | +38.89% | 18 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $330 → $333 | $272.98 | +21.99% | 9 | Aug 6, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $255 | $220.61 | +15.59% | 18 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $171 → $176 | $179.71 | -2.06% | 23 | Jul 17, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $8.93 | +79.17% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $35.04 | +54.11% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $78.56 | +24.75% | 17 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $44.12 | -22.94% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $132 → $133 | $98.08 | +35.60% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,133 → $1,135 | $724.54 | +56.65% | 20 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $348 → $328 | $432.66 | -24.19% | 10 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $8.27 | +33.01% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $12.84 | +71.34% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $10.21 | -2.06% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $61.67 | -48.11% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $16.31 | -32.56% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $25.00 | +372.00% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.23 | +258.74% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $137.37 | +217.39% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $446.40 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.31 | - | 1 | Jul 21, 2017 |
Alumis
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $4.05
Upside: +443.21%
Biohaven
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $15.00
Upside: +260.00%
Pfizer
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $32 → $33
Current: $23.76
Upside: +38.89%
Amgen
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $272.98
Upside: +21.99%
AbbVie
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $220.61
Upside: +15.59%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $171 → $176
Current: $179.71
Upside: -2.06%
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.93
Upside: +79.17%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $35.04
Upside: +54.11%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $78.56
Upside: +24.75%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $44.12
Upside: -22.94%
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $98.08
Upside: +35.60%
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $724.54
Upside: +56.65%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $432.66
Upside: -24.19%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $8.27
Upside: +33.01%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $12.84
Upside: +71.34%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $10.21
Upside: -2.06%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $61.67
Upside: -48.11%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $16.31
Upside: -32.56%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $25.00
Upside: +372.00%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.23
Upside: +258.74%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $137.37
Upside: +217.39%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $446.40
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $12.31
Upside: -